Skip to main content
Toggle navigation
Login
Search
Home
Conference Brochure
Tweets by JADPRO Live 2022
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
CE credit available
Pharmacology credit available
Back
Favorite
Email
Facebook
Tweet this
Print
Stephen Nowmos, Pharm.D., BCPS (he/him/his)
Medical Liaison
Novartis
Poster(s):
JL1011E: EPIK-B4: a phase 2, randomized study of metformin (MET) extended release (XR) +/− dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL)
Saturday, October 22, 2022
10:00 AM – 11:00 AM
ET
Email Stephen
